Abstract
Neurodegenerative Langerhans cell histiocytosis (ND-LCH) manifests several years after onset of LCH, with progressive neurological symptoms and characteristic brain imaging features. Although ND-LCH has a dismal neurological prognosis, distinct treatment strategies are not available owing to the unknown pathophysiology. We describe the case of a 6-year-old boy who developed left convergent strabismus four years after onset of multisystem LCH (MS-LCH). Although radiological imaging showed no abnormalities, the osteopontin level in the cerebrospinal fluid (CSF-OPN) was highly elevated without other abnormal CSF findings, leading to a diagnosis of ND-LCH. The patient received monthly intravenous immunoglobulin therapy for four years, without symptoms worsening. To investigate the relevance of OPN levels in LCH, we retrospectively analyzed serum and CSF OPN levels in eight LCH patients. Serum OPN levels were markedly elevated in the two MS-LCH patients with macrophage activation (400 and 445 ng/mL) compared to the other six patients (mean: 59 ng/mL). CSF-OPN levels were elevated in the ND-LCH patient (620 ng/mL) compared to the two patients with pituitary involvement (160 and 182 ng/mL), suggesting that the pathophysiology of ND-LCH reflects its inflammatory status. Analysis of CSF-OPN levels would be a useful tool to detect and treat ND-LCH.
Similar content being viewed by others
Data availability
All data generated in this study are included in this manuscript. Further inquiries can be directed to the corresponding author.
References
Morimoto A, Oh Y, Shioda Y, Kudo K, Imamura T. Recent advances in Langerhans cell histiocytosis. Pediatr Int. 2014;56:451–61.
Ikawa Y, Nishimura R, Araki R, Noguchi K, Muraoka M, Fukuda M, et al. Pathognomonic serum cytokine profiles identify life-threatening Langerhans cell histiocytosis. Br J Haematol. 2017;176:495–7.
Martin-Duverneuil N, Idbaih A, Hoang-Xuan K, Donadieu J, Genereau T, Guillevin R, et al. MRI features of neurodegenerative Langerhans cell histiocytosis. Eur Radiol. 2006;16:2074–82.
Héritier S, Barkaoui MA, Miron J, Thomas C, Moshous D, Lambilliotte A, et al. Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study. Br J Haematol. 2018;183:608–17.
Sakamoto K, Morimoto A, Shioda Y, Imamura T, Imashuku S, Japan LCH Study Group. Central diabetes insipidus in pediatric patients with Langerhans cell histiocytosis: results from the JLSG-96/02 studies. Pediatr Blood Cancer. 2019;66:e27454.
Imashuku S, Fujita N, Shioda Y, Noma H, Seto S, Minato T, et al. Follow-up of pediatric patients treated by IVIG for Langerhans cell histiocytosis (LCH)-related neurodegenerative CNS disease. Int J Hematol. 2015;101:191–7.
Eskstein O, McAtee CL, Greenberg J, Kumar A, Fein-Levy C, Smith T, et al. Rituximab therapy for patients with Langerhans cell histiocytosis-associated neurologic dysfunction. Pediatr Hematol Oncol. 2018;35:427–33.
Chohan G, Barnett Y, Gibson J, Reddel SWR, Barnett MH. Langerhans cell histiocytosis with refractory central nervous system involvement responsive to infliximab. J Neurol Neurosurg Psychiatry. 2012;83(5):573–5.
Allen CE, Flores R, Rauch R, Dauser R, Murray JM, Puccetti D, et al. Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside. Pediatr Blood Cancer. 2010;54:416–23.
McClain KL, Picarsic J, Chakraborty R, Zinn D, Lin H, Abhyankar H, et al. CNS Langerhans cell histiocytosis: common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer. 2018;124:2607–20.
Guennec LL, Decaix C, Donadieu J, Santiago-Ribeiro M, Martin-Duverneuil N, Levy R, et al. The cognitive spectrum in neurodegenerative Langerhans cell histiocytosis. J Neurol. 2014;261:1537–43.
Lamort AS, Giopanou I, Psallidas I, Stathopoulos GT. Osteopontin as a link between inflammation and cancer: the thorax in the spotlight. Cells. 2019;8:815.
Allen CE, Li L, Peters TL, Leung HE, Yu A, Man TK, et al. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. J Immunol. 2010;184:4557–67.
Idbaih A, Donadieu J, Barthez MA, Geissmann F, Bertrnd Y, Hermine O, et al. Retinoic acid therapy in “degenerative-like” neuro-langerhans cell histiocytosis: a prospective pilot study. Pediatr Blood Cancer. 2004;43:55–8.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have no conflicts of interest to declare.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Sakai, Y., Ikawa, Y., Takenaka, M. et al. A case of neurodegenerative Langerhans cell histiocytosis exhibiting high osteopontin in cerebrospinal fluid without specific radiological abnormalities. Int J Hematol 118, 661–665 (2023). https://doi.org/10.1007/s12185-023-03639-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-023-03639-2